Gastrointestinal safety of NSAIDs and over-the-counter analgesics

International Journal of Clinical Practice

Volumn 67, Issue SUPPL. 178, 2013, Pages 37-42

  Bjarnason, I ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; AZAPROPAZONE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; KETOROLAC; LUMIRACOXIB; METRONIDAZOLE; MISOPROSTOL; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; ROFECOXIB; SALAZOSULFAPYRIDINE;

BLEEDING; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DIET RESTRICTION; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROPATHY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; PATHOPHYSIOLOGY; PEPTIC ULCER BLEEDING; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; STOMACH EROSION; STOMACH HEMORRHAGE; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UPPER GASTROINTESTINAL BLEEDING; UPPER GASTROINTESTINAL TRACT;

EID: 84894259542     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12048     Document Type: Review

References (38)

1. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-47. (Pubitemid 23235480)
2. Hayllar J, Macpherson A, Bjarnason I. Gastroprotection and nonsteroidal anti-inflammatory drugs. Rational and clinical implications. Drug Saf 1992; 7: 86-105.
3. Somasundaram S, Hayllar J, Rafi S, Wrigglesworth JM, Macpherson AJS, Bjarnason I. The biochemical basis of NSAID-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30: 289-99.
4. Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)- induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol 2001; 61: 631-7. (Pubitemid 32239415)
5. Somasundaram S, Rafi S, Hayllar J et al. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID-induced injury to the rat intestine. Gut 1997; 41: 344-53. (Pubitemid 27428194)
6. Moore A, Bjarnason I, Cryer B et al. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol 2009; 7: 1156-63.
7. Bjarnason I, Scarpignato C, Takeuchi K, Rainsford KD. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther 2007; 26: 95-106. (Pubitemid 46889838)
8. Fenn GC. Controversies in NSAID-induced gastroduodenal damage-do they matter? Aliment Pharmacol Ther 1994; 8: 15-26.
9. Kaufman DW, Kelly JP, Sheehan JE et al. Nonsteroidal antiinflammatory drug use in relation to major gastrointestinal bleeding. Clin Pharmacol Ther 1993; 53: 485-94. (Pubitemid 23119438)
10. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-88. (Pubitemid 23281496)
11. Langman MJS, Weil J, Wainwright P et al. Risk of bleeding peptic ulcers associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.
12. Rodrigues LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72. (Pubitemid 24098698)
13. Henry D, Lim LL-Y, Rodrigues LAG et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6. (Pubitemid 26188573)
14. MacDonald TM, Morant SV, Robinson GC et al. Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-7. (Pubitemid 27499736)
15. Silverstein FE, Graham GY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241-9.
16. Bombardiner C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
17. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomised controlled trial. Celecoxib Long-term Arthritis Study. JAMA 2000; 284: 1247-55.
18. Bjarnason I, Thjodleifsson B. The murky world of the COX-2-selective agents. Inflammopharmacology 2005; 13: 381-93. (Pubitemid 41617800)
19. Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127: 1038-43. (Pubitemid 39345872)
20. Chan FK, Wong VW, Suen BY et al. Combination of a cyclo-oxygenase-2 inhibitor and a protonpump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a doubleblind, randomised trial. Lancet 2007; 369: 1621-6. (Pubitemid 46710125)
21. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. The effect of NSAIDs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292-7. (Pubitemid 17175676)
22. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAIDinduced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-8.
23. Tibble J, Sigthorsson G, Foster R, Scott D, Roseth A, Bjarnason I. Faecal calprotectin: A simple method for the diagnosis of NSAID-induced enteropathy. Gut 1999; 45: 362-6. (Pubitemid 29400711)
24. Bjarnason I, Zanelli G, Prouse P et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987; 2: 711-4. (Pubitemid 17125695)
25. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-9.
26. Bjarnason I, Price AB, Zanelli G et al. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology 1988; 94: 1070-4.
27. Maiden L, Thjodleifsson B, Seigal A et al. Longterm effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007; 5: 1040-5.
28. Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992; 33: 1204-8.
29. Hayllar J, Smith T, Macpherson A, Price AB, Gumpel M, Bjarnason I. Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease- modifying antirheumatic drugs. Arthritis Rheum 1994; 37: 1146-50. (Pubitemid 24313313)
30. Takeuchi K, Smale S, Premchand P et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196-202. (Pubitemid 43199690)
31. Hawkey C, Burnett I, Gold MS et al. Endoscopic evaluation of the gastro-duodenal tolerance of short-term analgesic treatment with 25 mg diclofenac- K liquid capsules. Aliment Pharmacol Ther 2012; 35: 819-27.
32. Doherty M, Hawkey C, Goulder M et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen / paracetamol in community-derived people with knee pain. Ann Rheum Dis 2011; 70: 1534-41.
33. Doyle G, Furey S, Berlin R et al. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther 1999; 13: 897-906. (Pubitemid 29312775)
34. Kellstein DE, Waksman JA, Furey SA, Binstok G, Cooper SA. The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. J Clin Pharmacol 1999; 39: 520-32. (Pubitemid 29356474)
35. Moore N, Le Parc JM, van Ganse E, Wall R, Schneid H, Cairns R. Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain. Int J Clin Pract 2002; 56: 732-4. (Pubitemid 36104536)
36. Rampal P, Moore N, Van Ganse E et al. Gastrointestinal tolerability of ibuprofen compared with paracetamol and aspirin at over-the-counter doses. J Int Med Res 2002; 30: 301-8. (Pubitemid 34823308)
37. Moore N. Forty years of ibuprofen use. Int J Clin Pract 2003; 135: 28-31. (Pubitemid 36458875)
38. Rainsford KD, Bjarnason I. NSAIDs: take with food or after fasting? J Pharm Pharmacol 2012; 64: 465-9.